Table 3.
Association of MCT1, MCT4, GLUT1 and CAIX plasma membrane expression with the clinicopathological parameters (categorical variables) in melanomas. Only expression in primary tumors was considered.
| MCT1 |
MCT4 |
GLUT1 |
CAIX |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Positive (%) | p | n | Positive (%) | p | n | Positive (%) | p | n | Positive (%) | p | |
| Gender | 0.516 | 0.045 | 0.425 | 0.506 | ||||||||
| Male | 102 | 34 (33.3) | 109 | 22 (20.2) | 108 | 13 (12.0) | 106 | 31 (29.2) | ||||
| Female | 109 | 41 (37.6) | 114 | 12 (10.5) | 114 | 10 (8.8) | 111 | 28 (25.2) | ||||
| Clinical stage | < 0.001 | 0.032 | 0.803 | 0.495 | ||||||||
| 0 + I + II | 110 | 26 (23.6) | 121 | 12 (9.9) | 121 | 14 (11.6) | 117 | 29 (24.8) | ||||
| III + IV | 86 | 42 (48.8) | 88 | 18 (20.5) | 86 | 9 (10.5) | 86 | 25 (29.1) | ||||
| Clark's level | 0.868 | 0.181 | 0.905 | 0.157 | ||||||||
| I + II + III | 48 | 16 (33.3) | 54 | 5 (9.3) | 50 | 6 (12.0) | 51 | 18 (35.3) | ||||
| IV + V | 124 | 43 (34.7) | 130 | 22 (16.9) | 132 | 15 (11.4) | 129 | 32 (24.8) | ||||
| Histological subtype | 0.561 | 0.029 | 0.434 | 0.440 | ||||||||
| Acral lentiginous | 27 | 10 (37.0) | 33 | 1 (3.0) | 36 | 4 (11.1) | 31 | 6 (19.4) | ||||
| Nodular | 74 | 27 (36.5) | 73 | 16 (21.9) | 73 | 10 (13.7) | 74 | 22 (29.7) | ||||
| Superficial spreading | 47 | 13 (27.7) | 52 | 6 (11.5) | 48 | 3 (6.3) | 50 | 11 (22.0) | ||||
| Anatomical site | 0.757 | 0.038 | 0.834 | 0.372 | ||||||||
| Limbs | 106 | 34 (32.1) | 113 | 12 (10.6) | 113 | 11 (9.7) | 109 | 30 (27.5) | ||||
| Trunk | 49 | 20 (40.8) | 52 | 14 (26.9) | 51 | 6 (11.8) | 53 | 18 (34.0) | ||||
| Head and neck | 48 | 17 (35.4) | 50 | 7 (14.0) | 50 | 6 (12.0) | 48 | 11 (22.9) | ||||
| Mucosa | 5 | 2 (40.0) | 5 | 0 (0.0) | 5 | 0 (0.0) | 4 | 0 (0.0) | ||||
| Ulceration | 0.143 | 0.598 | 0.273 | 0.396 | ||||||||
| Absent | 51 | 14 (27.5) | 58 | 8 (13.8) | 55 | 5 (9.1) | 55 | 18 (32.7) | ||||
| Present | 88 | 35 (39.8) | 88 | 15 (17.0) | 91 | 14 (15.4) | 88 | 23 (26.1) | ||||
| Peritumoral lymphocyte infiltration | 0.731 | 0.293 | 0.063 | 0.486 | ||||||||
| Absent | 22 | 8 (36.4) | 22 | 1 (4.5) | 23 | 0 (0.0) | 23 | 8 (34.8) | ||||
| Present | 74 | 24 (32.4) | 79 | 13 (16.5) | 76 | 11 (14.5) | 77 | 21 (27.3) | ||||
| Intratumoral lymphocyte infiltration | 0.138 | 0.054 | 0.185 | 0.448 | ||||||||
| Absent | 38 | 17 (44.7) | 41 | 2 (4.9) | 42 | 2 (4.8) | 38 | 11 (28.9) | ||||
| Present | 60 | 18 (30.0) | 62 | 11 (17.7) | 58 | 8 (13.8) | 63 | 14 (22.2) | ||||
| Tumor regression | 0.709 | 0.417 | 1.000 | 1.000 | ||||||||
| No | 96 | 35 (36.5) | 103 | 13 (12.6) | 101 | 12 (11.9) | 99 | 23 (23.2) | ||||
| Yes | 8 | 2 (25.0) | 9 | 2 (22.2) | 8 | 1 (12.5) | 9 | 2 (22.2) | ||||
| pT | 0.016 | 0.002 | 0.035 | 0.546 | ||||||||
| 1 + 2 | 57 | 13 (22.8) | 63 | 2 (3.2) | 61 | 3 (4.9) | 60 | 17 (28.3) | ||||
| 3 + 4 | 116 | 48 (41.4) | 122 | 24 (19.7) | 121 | 19 (15.7) | 120 | 29 (24.2) | ||||
| pN | 0.004 | 0.008 | 0.641 | 0.481 | ||||||||
| 0 + 1 | 146 | 43 (29.5) | 158 | 17 (10.8) | 158 | 16 (10.1) | 153 | 39 (25.5) | ||||
| 2 + 3 | 48 | 25 (52.1) | 50 | 13 (26.0) | 48 | 6 (12.5) | 49 | 15 (30.6) | ||||
| pM | 0.012 | 0.162 | 0.750 | 0.402 | ||||||||
| 0 | 169 | 53 (31.4) | 183 | 24 (13.1) | 181 | 19 (10.5) | 177 | 46 (26.0) | ||||
| 1 | 31 | 17 (54.8) | 30 | 7 (23.3) | 30 | 4 (13.3) | 30 | 10 (33.3) | ||||
| Locoregional recurrence | 0.313 | 0.002 | 0.170 | 0.083 | ||||||||
| No | 155 | 52 (33.5) | 164 | 19 (11.6) | 164 | 14 (8.5) | 158 | 38 (24.1) | ||||
| Yes | 43 | 18 (41.9) | 46 | 14 (30.4) | 45 | 7 (15.6) | 46 | 17 (37.0) | ||||
WT: wild-type.